About eloxx pharmaceuticals - ELOX
Eloxx Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of novel ribonucleic acid-modulating drug candidates. It focuses on the formulation of medicines to treat rare and ultra-rare premature stop codon diseases. The company was founded by Silvia Noiman on December 19, 2017 and is headquartered in Arlington, MA.
ELOX At a Glance
Eloxx Pharmaceuticals, Inc.
10 Court Street
Arlington, Massachusetts 02476
| Phone | 1-781-577-5300 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -5,995,000.00 | |
| Sector | Health Technology | Employees | 10 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
ELOX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | N/A |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
ELOX Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -599,500.00 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
ELOX Liquidity
| Current Ratio | 0.307 |
| Quick Ratio | 0.307 |
| Cash Ratio | 0.279 |
ELOX Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | N/A |
| Return on Equity | N/A |
| Return on Total Capital | 54.965 |
| Return on Invested Capital | N/A |
ELOX Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | -9.168 |
| Total Debt to Total Assets | 18.975 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |